Tridek-One

Tridek-One is a preclinical-stage biotechnology company operating in the autoimmune and inflammatory disease market, established in 2018 as a spin-off from the French National Institute of Health and Medical Research (Inserm).

The company was founded by Dr. Giuseppina Caligiuri and Professor Antonino Nicoletti, both researchers at Inserm with extensive backgrounds in immunology and vascular biology. Dr. Caligiuri is a practicing cardiologist and research scientist whose work has focused on the role of CD31 in cardiovascular immunobiology. Professor Nicoletti specializes in immunology, with research contributions in atherothrombosis and alloimmunity. Their collective research at Inserm's Unit 1148 formed the scientific basis for the company, and they continue to contribute to its R&D programs.

Tridek-One's core business revolves around developing first-in-class agonistic monoclonal antibodies that target immune checkpoint inhibitory receptors. The company's primary focus is on its anti-CD31 agonist program, which aims to restore immune balance by modulating overactive immune responses without causing broad immunosuppression. This is achieved through a platform developing dual-targeting bispecific antibodies that engage CD31, a receptor widely expressed on immune cells, to inhibit signals that lead to cell activation and inflammation. This approach is intended to offer a targeted immunomodulatory effect for diseases with significant unmet clinical needs.

The company's business model is centered on the research and development of these novel therapeutics, with the goal of advancing them through preclinical and eventually clinical trials. Its operations are financed by venture capital. Tridek-One secured an initial €3 million in a 2019 seed round from AdBio partners and Advent Life Sciences. This was followed in 2022 by a €16 million Series A round led by Pureos Bioventures, with participation from new and existing investors, including Bpifrance and Bioqube Ventures. These funds are designated for identifying development candidates, conducting IND-enabling studies, and expanding the organization. The company is led by CEO Laurence de Schoulepnikoff, a professional with over 25 years of experience in the pharma and biotech sectors, who joined in July 2022.

Keywords: autoimmune diseases, inflammatory diseases, immunotherapy, monoclonal antibodies, CD31 agonist, immune checkpoint inhibitors, immunomodulation, bispecific antibodies, Inserm spin-off, preclinical biotechnology, venture-backed biotech, therapeutic antibodies, immune balance, ITIM receptors, antibody engineering, autoimmune therapy, first-in-class therapeutics, drug development, life sciences, Paris biotech